健康元

Group Introduction
[Its Dual-Listed Companies] Joincare Pharmaceutical Group (Stock Code: 600380) Livzon Pharmaceutical Group (Stock Code: 000513 Hong Kong Stock Code: 01513)
img
Your location:
Homepage
/
/
/
Shenzhen Haibin Pharmaceutical Co., Ltd.

Shenzhen Haibin Pharmaceutical Co., Ltd.

  • Time of issue:2020-08-03 17:08
Views:

(Summary description) Shenzhen Haibin Pharmaceutical Co., Ltd. (hereinafter referred to as " Haibin Pharmaceutical") was established in 1989 and officially put into operation in 1992. It is a private enterprise and a whol

Shenzhen Haibin Pharmaceutical Co., Ltd.

(Summary description) Shenzhen Haibin Pharmaceutical Co., Ltd. (hereinafter referred to as " Haibin Pharmaceutical") was established in 1989 and officially put into operation in 1992. It is a private enterprise and a whol

  • Time of issue:2020-08-03 17:08
  • Views:
Information

   Shenzhen Haibin Pharmaceutical Co., Ltd. (hereinafter referred to as " Haibin Pharmaceutical") was established in 1989 and officially put into operation in 1992. It is a private enterprise and a wholly-owned subsidiary of Joincare Pharmaceutical Group Industry Co., Ltd. which is a domestic A-share listed company. Haibin Pharmaceutical is located in Yantian District, Shenzhen, a national-level eco-environment demonstration zone. The plant covers an area of 16,000 square meters with a building area of 26,800 square meters.

   Haibin Pharmaceutical is mainly engaged in the production of antibiotics, and its business scope includes chemical APIs and preparations, antibiotics, cardiovascular drugs and proprietary Chinese medicines. The main product varieties include a series of independently developed drugs, such as meropenem, imipenem, faropenem, Beineng, Suneng, piperacillin sodium tazobactam sodium for injection, cefoperazone sodium sulbactam sodium for injection, desloratadine tablets and irbesartan tablets. It has many GMP-compliant production lines, such as penicillin and cephalosporin powder production lines, carbapenem API production lines, lyophilized API and preparation production lines, chemical API production lines, and penicillin and chemical oral drug production lines, and has formed an annual production capacity of 80 million bottles of powder injection, 100 million tablets, 100 million capsules and 30 tons of APIs. 

      Since its establishment, Haibin Pharmaceutical has been adhering to the enterprise spirits of being "diligent, pioneering, rigorous and efficient" and the people-oriented business philosophy. After more than ten years of efforts, it has achieved remarkable results. It has successively won the titles of "Shenzhen Advanced Technology Enterprise" and "Guangdong Province Technology Innovation Advantage Enterprise". In 2001, it was rated as "Shenzhen High-tech Enterprise"; in 2003, it was rated as "Green Enterprise" in Shenzhen; in 2004, it was recognized as "Guangdong Food and Drug Safety Project Demonstration Base" by the Guangdong Food and Drug Safety Assurance Evaluation Committee"; in 2007, it passed the "Clean Production Enterprise" acceptance in Guangdong Province; in 2008, it was awarded the "Shenzhen Labor and Employment Advanced Enterprise" certificate issued by the Ministry of Labor and Social Security of Guangdong Province and passed the "high-tech enterprise" annual review; and in 2009, it passed the ISO14001 and OHSAS18001 system certification. The company has grown to a national second-class pharmaceutical industry enterprise with nearly 400 employees and annual sales of nearly 300 million yuan, and a credit rating of A grade. 


        New product R&D and process improvement are the driving forces for the sustainable development of enterprises and one of our core competitiveness. Shenzhen Haibin Pharmaceutical Co., Ltd. began research on a new generation of high-efficiency broad-spectrum antibacterial drug, carbapenem antibiotics, in 1999. The quality of meropenem raw materials and preparations has reached the standards of the United States Pharmacopoeia, and it has obtained a number of Chinese and world patents on meropenem production process. At present, the company focuses on the research and development of carbapenem series of antibiotics, and has not only basically completed the process research of new drugs such as imipenem, faropenem and biapenem, but also greatly optimized and innovated the raw material and branched chain technology of products. As brand-name products in today's antibiotics, this series of products have a surprising effect on uncontrollable infections. Their successful development will not only bring new and longer-term profit growth points to the company, but also certainly write a new chapter in the field of antibiotics in China.

        Quality is life. Shenzhen Haibin Pharmaceutical Co., Ltd. has established a quality management system that fully complies with GMP requirements. The Quality Department is responsible for drug inspection and the operation of the company's quality assurance system. Quality management personnel account for about 12% of the total number of employees, of which 50% have bachelor degree or above. The laboratory has complete function rooms such as aseptic testing room and microbial limit testing room equipped with advanced testing instruments and equipment, such as high-performance liquid chromatography, gas chromatography and infrared spectrophotometer, which can fully meet the needs of product testing. 

 

       At the same time, in June 2012, the German GMP certification body conducted the on-site inspection of the sterile meropenem preparation (powder for injection) production workshop of Haibin Pharmaceutical and concluded that the production met the EU-GMP requirements. Haibin Pharmaceutical received the EU-approved EU-GMP certificate issued by the certification body in early June with certificate number of 2012/14/55/M [issued in accordance with 2001/83/EC Directive 111(5)], which is valid for three years. In addition, in 2011, the sterile meropenem (API) passed the EU-GMP certification (see GGL No. 2011-051). So far, according to the available data, Haibin Pharmaceutical has become the first company in China to obtain the EU-GMP certification for sterile meropenem preparations (powder for injection). It is also a manufacturer of sterile APIs and preparations (powder for injection) that have passed the EU-GMP certification in China, which have a positive impact on the sales of Haibin Pharmaceutical in the EU regulated market and other markets in the future and further highlights the strong competitive edge of Haibin Pharmaceutical.

 

     As a member of the pharmaceutical industry, it is our duty to develop the pharmaceutical industry and safeguard human health. We believe that as long as we adhere to the goal of "sincerely dedicating ourselves to the health cause" and the style of "Care, kindness, rigorousness and seriousness", continuously innovate and strive work, Haibin Pharmaceutical will become a bright pearl in the Chinese pharmaceutical industry.

 

 

 Official website link:http://www.szhaibin.com

Scan the QR code to read on your phone

Quick Navigation

Service Hotline

Service

Hotline

Copyright © Joincare Pharmaceutical Group Industry Co., Ltd. All Rights Reserved.  Powered by:www.300.cn Zhuhai  粤ICP备14024104号